Mereo BioPharma (MREO) Return on Sales (2023 - 2025)
Mereo BioPharma (MREO) has disclosed Return on Sales for 3 consecutive years, with 250.86% as the latest value for Q3 2025.
- On a quarterly basis, Return on Sales rose 29617.0% to 250.86% in Q3 2025 year-over-year; TTM through Sep 2025 was 142.37%, a 9706.0% decrease, with the full-year FY2023 number at 2.95%, changed N/A from a year prior.
- Return on Sales was 250.86% for Q3 2025 at Mereo BioPharma, up from 29.23% in the prior quarter.
- In the past five years, Return on Sales ranged from a high of 250.86% in Q3 2025 to a low of 45.32% in Q3 2024.
- A 3-year average of 21.87% and a median of 2.63% in 2024 define the central range for Return on Sales.
- Peak YoY movement for Return on Sales: crashed -4305bps in 2024, then soared 29617bps in 2025.
- Mereo BioPharma's Return on Sales stood at 9.11% in 2023, then crashed by -398bps to 45.32% in 2024, then surged by 654bps to 250.86% in 2025.
- Per Business Quant, the three most recent readings for MREO's Return on Sales are 250.86% (Q3 2025), 29.23% (Q2 2025), and 71.59% (Q1 2025).